Premium
Abbvie Inc (0QCV)
LSE
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-02-27 | Mr. David Ryan PurdueSenior VP & Corporate Controller | -2,11k | 489,22k | Sale to Issuer | 232,08 | 9,01k | -18,96% |
| 2026-03-04 | Mr. David Ryan PurdueSenior VP & Corporate Controller | -5,23k | 1,22M | Vente | 233,56 | 3,78k | -58,04% |
| 2026-02-27 | Mr. Demetris D. CrumExec. VP & Chief HR Officer | -1,59k | 369,94k | Sale to Issuer | 232,08 | 7,91k | -16,76% |
| 2026-02-27 | Dr. Roopal B. ThakkarExec. VP of Research & Development and Chief Scientific Officer | -8,04k | 1,87M | Sale to Issuer | 232,08 | 55,37k | -12,67% |
| 2026-02-27 | Mr. Robert A. MichaelCEO & Chairman of the Board | -36,52k | 8,48M | Sale to Issuer | 232,08 | 178,74k | -16,97% |
| 2026-03-02 | Mr. Perry C. SiatisExec. VP, General Counsel & Secretary | -18,67k | 4,38M | Vente | 233,51 - 235,26 | 4,62k | -80,16% |
| 2026-02-27 | Mr. Perry C. SiatisExec. VP, General Counsel & Secretary | -14,85k | 3,45M | Sale to Issuer | 232,08 | 4,62k | -76,28% |
| 2026-02-27 | Dr. Azita Saleki-GerhardtExec. VP & COO | -16,31k | 3,78M | Sale to Issuer | 232,08 | 204,37k | -7,39% |
| 2026-02-27 | Mr. Jeffrey Ryan StewartExec. VP & Chief Commercial Officer | -23,81k | 5,53M | Sale to Issuer | 232,08 | 84,51k | -21,98% |
| 2026-02-27 | Dr. Nicholas J. DonoghoeExec. VP and Chief Business & Strategy Officer | -12,87k | 2,99M | Sale to Issuer | 232,08 | 74,43k | -14,75% |
| 2026-02-27 | Mr. Scott T. ReentsExec. VP & CFO | -21,64k | 5,02M | Sale to Issuer | 232,08 | 38,78k | -35,82% |
| 2026-02-25 | Mr. Perry C. SiatisExec. VP, General Counsel & Secretary | -22,38k | 1,28M | Derivative Exercise and Sale | 149,62 - 230,00 | 4,62k | - |
| 2025-08-12 | Dr. Azita Saleki-GerhardtExec. VP & COO | -42,37k | 6,08M | Derivative Exercise and Sale | 54,86 - 198,42 | 183,81k | - |
| 2025-08-05 | Dr. Nicholas J. DonoghoeExec. VP and Chief Business & Strategy Officer | -13,30k | 2,64M | Vente | 198,27 - 198,59 | 58,25k | -18,58% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
